Platelet function defects in adolescents with heavy menstrual bleeding

Haemophilia ◽  
2013 ◽  
Vol 20 (2) ◽  
pp. 249-254 ◽  
Author(s):  
H. L. Mills ◽  
M. S. Abdel-Baki ◽  
J. Teruya ◽  
J. E. Dietrich ◽  
M. D. Shah ◽  
...  
Keyword(s):  
Platelet Function ◽  
Heavy Menstrual Bleeding ◽  
Menstrual Bleeding

Outpatient Management of Heavy Menstrual Bleeding in Adolescent and Young Women with Inherited Platelet Function Disorders

2020 ◽  
Vol 33 (5) ◽  
pp. 489-493
Author(s):  
Christine M. Pennesi ◽  
Elisabeth H. Quint ◽  
Monica W. Rosen ◽  
Sarah D. Compton ◽  
Erica J. Odukoya ◽  
...  
Keyword(s):  
Platelet Function ◽  
Young Women ◽  
Heavy Menstrual Bleeding ◽  
Menstrual Bleeding ◽  
Outpatient Management ◽  
Platelet Function Disorders

Platelet function disorder in women with heavy menstrual bleeding in Eastern Uttar Pradesh

2021 ◽  
Vol 35 (1) ◽  
pp. 24
Author(s):  
Madhu Jain ◽  
Shuchi Jain ◽  
NishaRani Agrawal ◽  
Vijai Tilak ◽  
Ekhlak Mohammad ◽  
...  
Keyword(s):  
Platelet Function ◽  
Uttar Pradesh ◽  
Heavy Menstrual Bleeding ◽  
Menstrual Bleeding ◽  
Eastern Uttar Pradesh

scholarly journals Pilot study of novel lab methodology and testing of platelet function in adolescent women with heavy menstrual bleeding

2018 ◽  
Vol 83 (3) ◽  
pp. 693-701 ◽  
Author(s):  
Anne D Rocheleau ◽  
Ayesha Khader ◽  
Anh T P Ngo ◽  
Colin Boehnlein ◽  
Cara McDavitt ◽  
...  
Keyword(s):  
Pilot Study ◽  
Platelet Function ◽  
Heavy Menstrual Bleeding ◽  
Menstrual Bleeding ◽  
Adolescent Women

scholarly journals Iron Repletion Increases Platelet Aggregation and Reduces Platelet Count in Iron Deficient Premenopausal Women

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 3170-3170
Author(s):  
Benjamin Elstrott ◽  
Hari H.S. Lakshmanan ◽  
Hannah Stowe McMurry ◽  
Malinda T West ◽  
Sven Reid Olson ◽  
...  
Keyword(s):  
Platelet Count ◽  
Platelet Aggregation ◽  
Iron Deficiency ◽  
Platelet Function ◽  
Platelet Reactivity ◽  
Premenopausal Women ◽  
Heavy Menstrual Bleeding ◽  
Menstrual Bleeding ◽  
Iron Deficient ◽  
Post Infusion

Abstract Background: Iron deficiency, heavy menstrual bleeding, and anemia are interrelated conditions with high prevalence in women's health. Together, they impact an estimated 310 million premenopausal women worldwide. Iron deficiency has been associated with development of anemia as well as thrombocytosis. However, the effects of iron deficiency on platelet function remain unknown. Objective: We set out to investigate the impact of IV iron repletion on platelet function, platelet count, and other blood cell indices in iron deficient premenopausal women. Methods: We conducted a prospective single-center study of iron deficient premenopausal women who underwent iron repletion with a single dose of 1000 mg of low molecular weight iron. Pre-infusion and post-infusion blood samples were obtained for laboratory analysis. Standard of care monitoring of iron indices and complete blood counts were also included in the analysis. Pre-infusion rates of anemia and thrombocytosis were calculated using minimum hemoglobin and peak platelet count in the 6 months preceding iron infusion. Platelet function was quantified by Fluorescence-Activated Cell Sorting (FACS) quantification of platelet activation marker antibodies for GPIIb/IIIa (PAC1) and P-selectin (CD62P) after exposure to multiple platelet agonists. Platelet aggregation was assessed by flow of anticoagulated whole blood at a shear rate of 300 s -1 for 5 minutes through chambers coated with type I collagen, imaged with differential interference contrast optics, and quantitatively represented through computation of percent total surface coverage. Pre-infusion and post-infusion cell indices and aggregation data were compared by paired samples t-test. All statistical analyses were performed in GraphPad Prism (Version 8.0.0). Results: Thirteen patients were included in the analysis. Heavy menstrual bleeding was the suspected cause of iron deficiency in 83% of patients. Thrombocytosis was present in 15% of patients at pre-infusion and no patients at post-infusion. Average ferritin was 14 µg/L at pre-infusion and 126 µg/L at post-infusion. The peak platelet count within 6 months pre-infusion was 309 K/mm 3 (±89) vs. 274 (±64) K/mm 3 at post-infusion (p<0.05). The average change to 6-month pre-infusion peak and post-infusion platelet count was -35.2 K/mm 3 (95%CI: -66.2, -5.23). The mean 6-month minimum hemoglobin was 11.9 (±1.9) g/dL vs. 13.3 (±1.1) g/dL at post-infusion (p<0.005). Acquisition of FACS platelet reactivity data are ongoing, with preliminary results for the first 7 consecutively enrolled study patients displayed in Figure 1. Platelet aggregation measured at pre-infusion showed 14% surface coverage, with a significant increase to 29% at post-infusion (p < 0.05). None of the 13 women experienced a thrombotic event during the study period. Conclusion: Correction of iron deficiency results in decreased platelet count and improves platelet aggregation over collagen. Iron repletion may also improve platelet reactivity in response to physiologic agonists. These findings may suggest that iron deficiency impairs hemostasis and that correction of low iron may be even more critical for women with heavy menstrual bleeding. Figure 1 Figure 1. Disclosures Shatzel: Aronora Inc,: Consultancy.

scholarly journals A Multi-Institution Retrospective Study to Assess Bleeding Phenotype Among Patients with Platelet Function Disorders

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 3033-3033
Author(s):  
Divyaswathi Citla Sridhar ◽  
Robert F. Sidonio ◽  
Michael Silvey ◽  
Dunlei Cheng ◽  
Sanjay Ahuja
Keyword(s):  
Retrospective Study ◽  
Board Of Directors ◽  
Platelet Function ◽  
Burden Of Illness ◽  
Heavy Menstrual Bleeding ◽  
Menstrual Bleeding ◽  
Advisory Committees ◽  
Post Surgery ◽  
Platelet Function Disorders ◽  
Bleeding Episodes

Abstract Introduction: Platelet function disorders (PFD) clinically manifest with wide variability in mucocutaneous bleeding and significant hemorrhage post-surgery or trauma. The overall prevalence of PFD is not known, as there have not been large population-based studies. Treatment of these patients vary based on their bleeding phenotype. Additionally, the exact bleeding phenotype of many qualitative platelet defects are not well described in literature. This study aims to describe the bleeding phenotype among patients with different (PFD). Methods: This is a retrospective study among patients with PFD conducted at 3 Hemophilia Treatment centers - HOG Center for Bleeding and Clotting Disorders of CHOA, Children's Mercy hospital HTC and Rainbow babies & Children's hospital HTC. Institutional IRB approval was obtained at all 3 institutions. We collected data on demographics, bleeding symptoms at presentation, bleeding episodes, management of these bleeds over a 6-year time period (2015-2020). Results: We identified 131 patients with PFDs at 3 institutions. This included 67 males (51.2%) and 64 females (48.8%). Among 131 patients, 72 patients (55%) had a defect in platelet agonist interaction/receptor defect (ADP/Epinephrine/Collagen/TXA2/Arachidonic acid), 37 patients (28.2%) had delta storage pool defect, 8 patients (6.1%) had Glanzmann thrombasthenia, 7 patients (5.3%) had a platelet release defect, 3 patients (2.3%) with an alpha granule defect, 2 patients (1.5%) with Bernard Soulier syndrome and 1 patient (0.76%) with Wiskott Aldrich syndrome. The most common bleeding symptoms at presentation were epistaxis (40.4%), followed by easy bruising (31.3%), heavy menstrual bleeding (15.2%), gum bleeding (6.87%) and gastrointestinal bleeding (4.58%). From 2015-2020, a total of 162 bleeds were documented, and 68 patients (51.9%) with at least 1 documented episode of bleeding. 67.2% of these bleeds were spontaneous, 12.3% were secondary to trauma, 4.9% after a dental procedure, 2.5% after surgery and 0.6% after child birth. The most common type of bleeding episode in diagnosed patients included epistaxis (50%), heavy menstrual bleeding (17.9%), skin/soft tissue bleed (5.5%), gastrointestinal (5.5%) and dental/tooth related (4.9%). 93 bleeding episodes (57.4%) required some form of treatment in various settings - home (73%), clinic (15%), emergency room (7.5%), hospitalization (14%) and ICU stay (2%). Treatments included antifibrinolytics (68.8%), recombinant factor VIIa (11.8%), desmopressin (9.6%), hormonal therapy (9.6%) and platelet transfusions (5.3%). Conclusions: Our study helps characterize the bleeding phenotype and management in patients with various PFD. This data is crucial in understanding the burden of illness among different types of PFD, and to understand health care utilization to better serve the needs of these poorly characterized patients. Disclosures Sidonio: Sanofi, Takeda, Octapharma, Bayer, Biomain, Grifols, Kedrion, Genentech. Catalyst, Guardian Therapeutics, Novo Nordisk, Hema Biologics, Uniqure.: Consultancy, Honoraria. Silvey: Genentech: Speakers Bureau; Sanofi Genzyme: Membership on an entity's Board of Directors or advisory committees. Ahuja: XaTek, Inc: Patents & Royalties; Sanofi: Membership on an entity's Board of Directors or advisory committees; Takeda: Other: DSMB member ; Genentech: Membership on an entity's Board of Directors or advisory committees.

Sign in / Sign up

Export Citation Format

Share Document